HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,200 shares, a growth of 60.0% from the March 31st total of 2,000 shares. Based on an average daily volume of 600 shares, the days-to-cover ratio is currently 5.3 days.
HLS Therapeutics Stock Down 7.5 %
HLTRF opened at $3.56 on Monday. HLS Therapeutics has a 12 month low of $2.60 and a 12 month high of $4.95. The company has a 50 day moving average of $3.34 and a 200 day moving average of $3.35.
Analysts Set New Price Targets
Separately, Raymond James lowered their price objective on HLS Therapeutics from $6.50 to $5.00 and set a “market perform” rating on the stock in a research note on Monday, March 18th.
About HLS Therapeutics
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Read More
- Five stocks we like better than HLS Therapeutics
- How to Evaluate a Stock Before BuyingÂ
- Western Digital Slips Despite EPS Beat and Raise – Buy Time?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Is the Financial Sector Poised for a Major Directional Move?
- Stock Splits, Do They Really Impact Investors?
- 3 Stocks With Unusual Call Option Buying Activity
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
